Our replication data included 15 datasets—two existing in silico datasets and 13 datasets for de novo genotyping (Table 1). The in silico dataset from the USA came from an existing GWAS of AN genotyped using the Illumina HumanHap610 platform (Illumina, San Diego, CA, USA)53 and the other in silico dataset came from Estonian Genome Center (www.biobank.ee) and was genotyped using the Illumina OmniExpress array. De novo genotyped samples included newly collected AN cases and controls from members of the GCAN and samples from the same sites as the discovery samples that had failed GWAS QC (including saliva and whole genome amplified samples). De novo SNP genotyping was carried out using the iPLEX Gold Assay (Sequenom, Inc., San Diego, CA, USA). SNPs with poor Sequenom design metrics were replaced with high-LD proxies. Sample and SNP QC were performed within each replication dataset. QC included checking for sex inconsistencies and exclusions based on sample call rate <80%, SNP call rate <90% and exact Hardy-Weinberg Equilibrium (HWE) p<0.0001. In total, replication genotypes (in silico and de novo) of 76 prioritized SNPs and 27
